fbpx

News

Lundbeckfonden Ventures News

  BONESUPPORT AB, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced that a comprehensive review article summarizing available published and presented data for composite products containing calcium sulphate and hydroxyapatite, extensively refers to preclinical studies and clinical applications published on CERAMENTT’BONE VOID...
Study presented at the Combined Orthopaedic Research Society Meeting in Venice, Italy   BONESUPPORT AB, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced results from a five-year follow-up study on patients treated with CERAMENTT’BONE VOID FILLER, as presented at the Combined Orthopaedic Research...
  . Leading US centers in food allergy will be involved in an NIH-funded CoFAR study, coordinated by Dr. Sampson and Dr. Jones in collaboration with DBV’ team. CoFAR6 study will help to better characterize the mechanisms of action of epicutaneous immunotherapy DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new approach...
This Proof of concept study aims to capitalize on DBV’s safe and non-invasive technology and Inserm’s unique expertise to address refractory Hemophilia A, a severe orphan disease with no cost-effective and convenient treatment today available to patients DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies,...
  Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that it has appointed Michael Narachi as Chairman of the Board of Directors. Michael currently serves as President and Chief Executive Officer of Orexigen Therapeutics, Inc. Michael has 29 years...
Stallergenes to exercise option to develop and commercialize a birch allergy new product DBV eligible for milestone payments and royalties on Stallergenes’ net sale Stallergenes acquires an equity position in DBV Stallergenes S.A. (Euronext Paris: GENP), worldwide leader in allergen immunotherapy, and DBV Technologies (Euronext Paris: DBV), creator of Viaskin® for the treatment of allergies,...
  The Independant Data and Safety Monitoring Board (DSMB) recommends VIPES continuation without modifications DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today its topline financial results for first nine months 2013 and provided a clinical update on VIPES (Viaskin Peanut’s Efficacy and Safety),...
Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces positive results from its Phase II study of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients. The study showed that APD515 significantly reduced the symptoms of dry mouth (the primary endpoint) compared to placebo. APD515 is...
Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC”) relating to the proposed initial public offering of its common stock. All shares...
1 45 46 47 48 49 58

Lundbeckfonden Ventures

News

Acacia Pharma Group PLC – Acacia Pharma Group plc: Notice of Interim Results
12. August 2019
Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)
31. July 2019
BONESUPPORT HOLDING AB (publ) – Publishes Q2 2019 Interim report
25. July 2019